



dm

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

John BRASSIL et al.

Group Art Unit: 1651

Application No.: 10/768,167

Examiner: S. SAUCIER

Filed: February 2, 2004

Docket No.: 040219.04

For: APPARATUS AND METHOD FOR DETERMINING EFFECTS OF A SUBSTANCE ON
AN ORGAN

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- ☒ 2. In accordance with 37 CFR §1.98(a)(2)(ii), copies of any U.S. patents and patent application publications are not attached.

- ☒ 3. Reference 2 corresponds to reference 4.

Respectfully submitted,



William P. Berridge
Registration No. 30,024

Christopher J. Wheeler
Registration No. 60,738

WPB:CJW/clf

Date: August 31, 2007

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

<p>DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461</p>
--


Sheet 1 of 2

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 040219.04		APPLICATION NO. 10/768,167	
INFORMATION DISCLOSURE STATEMENT							
(Use several sheets if necessary)							
				APPLICANT(S) John BRASSIL et al.			
				FILING DATE February 2, 2004		GROUP 1651	
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Name			
	1	5,494,822	02/27/1996	Sadri			
	2	5,989,918	11/23/1999	Dietz et al.			
	3	6,673,594	01/06/2004	Owen et al.			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation	
	4	WO 98/09166	03/05/1998	WIPO			
	5	EP 1 208 748 A1	08/24/2000	Europe			
OTHER DOCUMENTS							
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)					
	6	11/802,064, 05/18/2007, Curtis et al.					
	7	11/802,059, 05/18/2007, Curtis et al.					
	8	11/598,800, 11/14/2006, Brassil et al.					
	9	"Human Data Before Human-Trials Improving Drug Discovery and Development Productivity with Ex Vivo Metrics," Katzenbach Partners LLC, 2005, pp. 1-22.					
	10	"Perfusion of the isolated rat liver," Curtis, C.G. et al., Proceedings of the Physiological Society, 12/1970, pp. 14P-15P.					
	11	"Degradation of [³ H]Chondroitin 4-Sulphate and Re-utilization of the [³ H]Hexosamine Component by the Isolated Perfused Rat Liver," Macnicoll, Alan D. et al., Biochem. J. (1980), Vol. 186, pp. 279-286.					
	12	"Utilization by the Isolated Perfused Rat Liver of N-Acetyl-D-[1- ¹⁴ C]galactosamine and N-[³ H]Acetyl D-galactosamine for the Biosynthesis of Glycoproteins," MacNicol, Alan D. et al., Biochem. J., (1978) Vol. 174, pp. 421-426.					
	13	"NMR study of the whole rat bile: the biliary excretion of 4-cyano-N, N-dimethyl aniline by an isolated perfused rat liver and a liver in situ," Ryan, David A. et al., Journal of Pharmaceutical & Biomedical Analysis, 1995, Vol. 13, No. 6, pp. 735-745.					
	14	"Liver as major organ of phenol detoxication?," Powell, G. et al., Nature, 11/15/1974, Vol. 252, pp. 234-235.					
	15	"Oxidation of Sodium Sulphide by Rat Liver, Lungs and Kidney," Bartholomew, Terrence C. et al., Biochemical Pharmacology, 1980, Vol. 29, pp. 2431-2437.					
	16	"The metabolic sulphation of polyethyleneglycols by isolated perfused rat and guinea-pig livers", Roy, A. B. and Maggs, J. et al., Xenobiotica, 1987, Vol. 17, No. 6, pp. 725-732.					
	17	"Octan-2-sulphate degradation in the isolated perfused rat liver", Maggs, J. et al., Biochemical Pharmacology, 1984, Vol. 33, No. 5, pp. 827-829.					
	18	Isolated Perfused Liver Technology for Studying Metabolic and Toxicological Problems, Powell, G.M. et al., 1989, Vol. 7, No. 1, pp. 53-86.					
EXAMINER						DATE CONSIDERED	
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: August 31, 2007



Sheet 2 of 2

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE	ATTY DOCKET NO. 040219.04	APPLICATION NO. 10/768,167
INFORMATION DISCLOSURE STATEMENT				
(Use several sheets if necessary)			APPLICANT(S) John BRASSIL et al.	
			FILING DATE February 2, 2004	GROUP 1651
OTHER DOCUMENTS				
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)		
	19	"Organ Perfusion and Mass Spectrometry: A Timely Merger for Drug Development," Curtis, C. Gerald et al., <i>Current Topics in Medicinal Chemistry</i> , 2002, Vol. 2, pp. 77-86.		
	20	<i>The Use of Isolated Perfused Organs</i> , Curtis, C. G. et al., pp. 295-302.		
	21	"Predictive Models for Tissue Metabolism-Screening Using Organ Perfusion Methods," Curtis, G., CPSA Digest 2001, http://www.milestonedevelopment.com/CPSA/2001/day3oa3.html .		
	22	"Alterations of the renal function in the isolated perfused rat kidney system after in vivo and in vitro application of S-(1,2-dichlorovinyl)-L-cysteine and S-(2,2-dichlorovinyl)-L-cysteine," Ilinskaja, O. and Vamvakas, S., <i>Arch Toxicol</i> (1996), vol. 70, pp. 224-229.		
	23	A New Paradigm in Perfusion, http://res-del.com/resources/AQIX_RS-L.pdf .		
	24	"The Rate of Induction of Hypothermic Arrest Determines the Outcome in a Swine Model of Lethal Hemorrhage," Alam, H. et al., <i>The Journal of TRAUMA Injury, Infection, and Critical Care</i> , 11/2004, Vol. 57, No. 5, pp. 961-969.		
EXAMINER			DATE CONSIDERED	
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Date: August 31, 2007